ACOG Reaffirms COVID-19 Vaccination During Pregnancy as Studies Confirm Safety of SGLT2 Inhibitors for Type 2 Diabetes

The American College of Obstetricians and Gynecologists (ACOG) has reaffirmed its support for COVID-19 vaccination during pregnancy, citing its importance in protecting maternal and fetal health. Meanwhile, new real-world evidence highlights the safety of SGLT2 inhibitors dapagliflozin and empagliflozin for managing type 2 diabetes. Additionally, EVERSANA and Waltz Health have announced a collaborative effort aimed at addressing drug affordability and improving patient access to medications.

ACOG’s renewed endorsement emphasizes the critical role of COVID-19 vaccines in reducing risks associated with severe illness during pregnancy. The organization continues to advocate for widespread vaccination among pregnant individuals as part of broader public health measures. Separately, findings from real-world studies provide further confirmation regarding the safety profile of SGLT2 inhibitors dapagliflozin and empagliflozin, which are commonly prescribed for type 2 diabetes management. These results align with previous clinical trial data supporting their use in diverse patient populations. In another development, EVERSANA and Waltz Health have joined forces to tackle rising drug costs by leveraging innovative solutions designed to enhance affordability and ensure equitable access to essential treatments across healthcare systems.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 28, 2025

Author

Mark Chiang